Vasculitis & polymyalgia rheumatica

Long-term outcome and clinicopathological characteristics of propylthiouracil-induced anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a case-control study

Clin Exp RheumatolPublished Retrospective case-control study

Authors' conclusion

Patients with PTU-induced AAGN demonstrated distinct clinical features and more favourable renal outcomes despite persistent positivity of MPO-ANCA, indicating a less aggressive disease course compared to primary AAGN.

Study context

Population
Patients with ANCA-associated glomerulonephritis (AAGN) who underwent diagnostic renal biopsies at Jinling Hospital, January 2005–December 2020
Participants
25 vs 379
Comparison
Propylthiouracil (PTU)-induced AAGN vs primary AAGN
  • PTU-induced AAGNn = 25
  • Primary AAGNn = 379reference
Outcome
Long-term renal outcomes (renal survival)
Methodological detailssingle-centre, renal biopsy-based
  • Single-centre
  • Renal biopsy-based

Main finding

As reported in the abstract

Renal survival (Kaplan-Meier)
  • PTU-induced AAGN vs Primary AAGN: P = 0.018

Observational data: associations, not effects.

Further findings

Clinical features at baseline

Lower serum creatinine and higher MPO-ANCA titres in PTU-induced vs primary AAGN

Histopathology

Crescentic and focal lesions predominant in PTU-induced group, with higher proportion of normal glomeruli and lower percentage of global sclerosis

Renal non-remission and relapse

Numerically lower, though statistically non-significant, rates in PTU-induced AAGN; treatment regimens comparable

MPO-ANCA positivity during follow-up · prolonged follow-up

Serum MPO-ANCA positivity persisted in most PTU-induced AAGN patients

Original publication

Long-term outcome and clinicopathological characteristics of propylthiouracil-induced ANCA-associated glomerulonephritis: a case-control study. Clin Exp Rheumatol. Published 24 June 2025. doi:10.55563/clinexprheumatol/johu1h

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.